Stuart Poulton - 28 Feb 2023 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, Chief Development Officer
Signature
/s/Nancy Smith as Attorney-in-Fact for Stuart Poulton
Issuer symbol
KPTI
Transactions as of
28 Feb 2023
Net transactions value
$0
Form type
4
Filing time
02 Mar 2023, 16:38:39 UTC
Previous filing
17 Feb 2023
Next filing
01 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +95,000 +148% $0.000000 159,131 28 Feb 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.